Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized Controlled, add-on Phase 2/3 Study of the Safety and Efficacy of Meplazumab in Patients With COVID-19

NCT05113784 is registered in ClinicalTrials.gov with Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd as lead sponsor.

NCT NCT05113784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized Controlled, add-on Phase 2/3 Study of the Safety and Efficacy of Meplazumab in Patients With COVID-19
Lead sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Phase
Phase 2/3
Overall status
Completed
Start date
January 21, 2022
Completion date
October 8, 2022
Enrollment
150 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19